Literature DB >> 34993728

Analysis of children with Henoch-Schonlein purpura secondary to infection.

Can Liu1, Lingli Luo2, Min Fu2, Zhengqiu Li2, Jianlong Liu2.   

Abstract

OBJECTIVES: Henoch-Schonlein purpura (HSP) is the most common childhood vasculitis, infection is the most essential inducement. We hypothesized that infection could impact the blood routine characteristics and/or outcome of vasculitis. Thus, we aim to find the most common infectious agent in HSP patients and identify convenient indicators to predict renal involvement in HSP patients with infection.
METHOD: We conducted a retrospective study of 208 HSP children and 98 healthy children. Clinical parameters were compared in those cases.
RESULTS: A total of 68.75% of patients were infected with various pathogens. The mean platelet volume (MPV) (P < 0.02) was lower in HSP patients with infection than patients without infection. Mycoplasma pneumoniae (MP) infection accounted for the largest proportion (45.77%). MPV in HSP nephritis (HSPN) group was lower than in HSP patients (excluded renal involvement) in patients with MP infection. Logistic regression analysis found that age and MPV were risk factors for the occurrence of MP-infected HSPN. The receiver operating characteristic curve (ROC) analysis showed that the combination of MPV with the onset age at the optimal cut-off point had 81% sensitivity in predicting whether HSP patients with MP infection would develop into HSPN.
CONCLUSIONS: Our research revealed that MP was the most commonly infected pathogen of children's HSP. MPV was an essential predictor of nephritis in HSP patients with MP infection. This discovery can prompt clinical treatments as well as reduce costs. Key Points • Mycoplasma pneumoniae (MP) accounts for the largest proportion in HSP children with infection. • MPV can be used as a predictor for the development of MP-triggered HSP to HSPN.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Henoch–Schonlein purpura; Henoch–Schonlein purpura nephritis; Mean platelet volume; Mycoplasma pneumonia

Mesh:

Year:  2022        PMID: 34993728     DOI: 10.1007/s10067-021-06007-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins.

Authors:  Janet M M Gardner-Medwin; Pavla Dolezalova; Carole Cummins; Taunton R Southwood
Journal:  Lancet       Date:  2002-10-19       Impact factor: 79.321

2.  EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.

Authors:  S Ozen; N Ruperto; M J Dillon; A Bagga; K Barron; J C Davin; T Kawasaki; C Lindsley; R E Petty; A M Prieur; A Ravelli; P Woo
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

3.  Hemotologic Indices for Predicting Internal Organ Involvement in Henoch-Schönlein Purpura (IgA vasculitis).

Authors:  Zeynep C Özdemir; Nuran Çetin; Yeter Düzenli Kar; Halil O Öcal; Muzaffer Bilgin; Özcan Bör
Journal:  J Pediatr Hematol Oncol       Date:  2020-01       Impact factor: 1.289

4.  Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study.

Authors:  Outi Jauhola; Jaana Ronkainen; Olli Koskimies; Marja Ala-Houhala; Pekka Arikoski; Tuula Hölttä; Timo Jahnukainen; Jukka Rajantie; Timo Ormälä; Matti Nuutinen
Journal:  Arch Dis Child       Date:  2010-09-16       Impact factor: 3.791

5.  Platelet Counts in Children With Henoch-Schonlein Purpura--Relationship to Renal Involvement.

Authors:  Ahmet Taner Elmas; Yilmaz Tabel
Journal:  J Clin Lab Anal       Date:  2014-11-10       Impact factor: 2.352

6.  Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome.

Authors:  R Blanco; V M Martínez-Taboada; V Rodríguez-Valverde; M García-Fuentes; M A González-Gay
Journal:  Arthritis Rheum       Date:  1997-05

Review 7.  Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review.

Authors:  Raquel López-Mejías; Santos Castañeda; Fernanda Genre; Sara Remuzgo-Martínez; F David Carmona; Javier Llorca; Ricardo Blanco; Javier Martín; Miguel A González-Gay
Journal:  Autoimmun Rev       Date:  2018-01-17       Impact factor: 9.754

Review 8.  Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge.

Authors:  Maryam Piram; Alfred Mahr
Journal:  Curr Opin Rheumatol       Date:  2013-03       Impact factor: 5.006

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

Review 10.  Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps.

Authors:  Louise Oni; Sunil Sampath
Journal:  Front Pediatr       Date:  2019-06-27       Impact factor: 3.418

View more
  3 in total

1.  Association of Pediatric Vasculitis Activity Score with immunoglobulin A vasculitis with nephritis.

Authors:  Begüm Avcı; Tuba Kurt; Fatma Aydın; Elif Çelikel; Zahide Ekinci Tekin; Müge Sezer; Nilüfer Tekgöz; Cüneyt Karagöl; Serkan Coşkun; Melike Mehveş Kaplan; Umut Selda Bayrakçı; Banu Acar
Journal:  Pediatr Nephrol       Date:  2022-07-27       Impact factor: 3.651

2.  Development and validation of a nomogram to predict recurrence in children with Henoch-Schönlein purpura.

Authors:  Danyang Song; Yajing Jiang; Qiuju Zhao; Jinling Li
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  Immunoglobulin A vasculitis induced by atypical pneumonia infection with Chlamydophila pneumonia.

Authors:  Seung Ah Kang; Suha Abu Khalaf; Taylor Nelson
Journal:  IDCases       Date:  2022-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.